Vimarsana
Biggest News Aggregation in the World

Subjective Units News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Subjective Units. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Subjective Units Today - Breaking & Trending Today

Vistagen Reports Fiscal Year 2024 Financial Results and Provides Corporate Update - Vimarsana News

Vistagen Reports Fiscal Year 2024 Financial Results and Provides Corporate Update

11.06.2024 - Vistagen (Nasdaq: VTGN), a neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, ...

7 Stocks Under $15 Predicted to Boom in the Next 2 Years - Vimarsana News

7 Stocks Under $15 Predicted to Boom in the Next 2 Years

Discover seven promising stocks priced under $15, leading in sectors like financial services, biotechnology, and energy.

Could EMDR Therapy Help You Unpack Trauma? - Vimarsana News

Could EMDR Therapy Help You Unpack Trauma?

A few months ago, I was watching Law & Order: SVU. In this particular scene, Olivia Benson (Mariska Hargitay) sits across from her therapist. The therapist holds her finger in front of Olivia’s eyes and moves it back and forth while talking about stressful situations like you would in a regular therapy session. What’s all that about, I thought. A quick Google search told me I was watching an EMDR (eye movement desensitization and reprocessing) session, a type of psychotherapy that’s primarily us

Source: yahoo.com
First Participant Enrolled in Phase 3 Trial of Fasedienol for Social Anxiety Disorder - Vimarsana News

First Participant Enrolled in Phase 3 Trial of Fasedienol for Social Anxiety Disorder

Vistagen has enrolled the first participant in the PALISADE-3 phase 3 trial of fasedienol for the treatment of social anxiety disorder.

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q3 2024 Earnings Call Transcript - Vimarsana News

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q3 2024 Earnings Call Transcript

VistaGen Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.22, expectations were $-0.31.